Treatment response patterns and effect size over time in exclusively placebo-controlled trials. Treatment response patterns and effect size over time in.

Slides:

Advertisements

Similar presentations

Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Duloxetine on Pain, Function, and Quality.

Advertisements

Copyright © 2017 American Academy of Pediatrics.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

A: Box plot comparing the average changes in HbA1c between surgery and medical/lifestyle treatments in the first reports of the 11 RCTs published to date.

A: Kaplan-Meier estimate of time to first LLA

Differences in the glycated hemoglobin (HbA1c) levels.

Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.

Selected efficacy and safety parameters.

Moderate-intensity exercise reduces fatigue and improves mobility in cancer survivors: a systematic review and meta-regression Amy M Dennett, Casey L.

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

Glycated hemoglobin (HbA1c) trajectories among children during the first 5 years after diagnosis of type 1 diabetes, stratified by diagnostic era and diagnostic.

The association between mean annual temperature and diabetes incidence in the USA over the period 1996–2009. The association between mean annual temperature.

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Estimated HR as a function of absolute change in glycated hemoglobin (HbA1c; from index to measurement 22–26 months after). Estimated HR as a function.

Mathematical modeling of bubble formation in insulin pump cartridges (3 mL solid line, 2 mL dotted line, and 1.8 mL dashed line) and lines during an increase.

Change in HbA1c and weight compared with baseline variables for the liraglutide group and the placebo group. Change in HbA1c and weight compared with baseline.

Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.

Scatterplot showing the association between baseline weight and weight change at 1 year, relative to baseline for each treatment group. Scatterplot showing.

Scatterplot showing the association between change in HbA1c at 1 year and weight change at 1 year, relative to baseline for each treatment group. Scatterplot.

Estimated HR as a function of mean residual of glycated hemoglobin (HbA1c) measurements to the line connecting index HbA1c and HbA1c measurement 22–26 months.

Temporal patterns of insulin sensitivity (A), C-peptide index (B), C-peptide oDI (C), and HMWA (D) in the three racial/ethnic groups with the three treatments.

A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs.

Inverse correlations between age and the M value (A), between age and NOx FSR (B), and between age and either ADMA (C) or SDMA (D) concentrations. Inverse.

Sagittal view of hypothalamus showing a significant reduction in CBF 15 and 30 min after application of intranasal insulin compared with placebo in the.

(A) Glucose values (mean +SEM) during continuous glucose monitoring while consuming whey protein (solid lines and filled circles) or placebo (broken lines.

Predicted percentage of home discharge by diabetes group adjusting for all variables listed in the age-centered logistic regression model with examination.

—ROC curves for each simple test compared with NCS (gold standard) plotting the sensitivity versus 1-specificity (the false-positive rate) for different.

Forest plot summarizing the primary analysis and all sensitivity analyses. a90-day grace period. bStratified by diabetic retinopathy screening in the year.

Saxagliptin improves glycemic control in younger and older individuals with type 2 diabetes. Saxagliptin improves glycemic control in younger and older.

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

Observed RW, modeled, and published trial estimates of HbA1c change from baseline. Observed RW, modeled, and published trial estimates of HbA1c change.

The effect of PAD and infection on outcome of cast treatment

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

Effect of age, sex, race/ethnicity, and obesity on the relation of glycemic measures to Si and AIR. In linear regression models with Si as the dependent.

Khadijah Breathett et al. JCHF 2017;5:

Incidence of childhood type 1 diabetes in Western Australia from 1985 through Incidence of childhood type 1 diabetes in Western Australia from 1985.

Forest plot and pooled estimates of the effect of NAFLD on the risk of incident diabetes in 16 eligible studies, stratified by length of follow-up (FU)

Crude and adjusted HbA1c change by medication adherence group (proportion of days covered (PDC)) by linear regression, controlling for age, age2, gender,

Effect of empagliflozin on efficacy parameters at week 18.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Difference in average school grades between offspring born to women with type 1 diabetes and the matched control children, by maternal third trimester.

Trends in mortality by age-groups and select CVDs among adults with diabetes. Trends in mortality by age-groups and select CVDs among adults with diabetes.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

A: Forest plot of the HR of AE of bone fracture between the saxagliptin and placebo groups across subgroups by demographic and medical history parameters.

Changes (means±posterior SDs) in HbA1c (A), fasting glucose (B), and body weight (C) by treatment condition based on missing not at random (MNAR) analyses.

HRs for type 2 diabetes by category of age at menarche in the EPIC-InterAct study. HRs for type 2 diabetes by category of age at menarche in the EPIC-InterAct.

Median (interquartile range) of sensor glucose (A) and insulin delivery (B) during closed-loop (solid red line and red shaded area) and control period.

Pooled analysis of association between (nonexclusive) breast-feeding and childhood-onset type 1 diabetes in studies investigating ∼2 weeks (nonexclusive)

ROC curves for cardiovascular events, all-cause mortality, and disease progression. ROC curves for cardiovascular events, all-cause mortality, and disease.

A: Probability of SICH by baseline glucose level.

Time course of HbA1c (A), FPG (B), body weight (C), SMPG (D), and lipase (E) from week 0 to week 26. Time course of HbA1c (A), FPG (B), body weight (C),

Progression to micro- or macroalbuminuria.

A: Forest plot of Peto odds ratios (ORs) of main glycemic end points, as defined in each trial, from published RCTs of bariatric/metabolic surgery compared.

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Visualization of prescriptive algorithm: provider dashboard prototype.

Plots of average estimated and measured GFR vs

Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Doses of trial medication in the liraglutide groups (A) and in the.

A: Probability of retinopathy-free survival.

Predicted, unadjusted prevalence of aggregate MVD (retinopathy, nephropathy, and/or neuropathy) (A), nephropathy (B), retinopathy (C), and neuropathy (D)

Differences in the values of HbA1c variables between the retinopathy-positive and retinopathy-negative groups at year 20. Differences in the values of.

Glycemic profile at time of recruitment of women with ICP (n = 19) and uncomplicated pregnancy (n = 23) using a CGMS (Medtronic iPro2) over 3 days. Glycemic.

Changes in urinary albumin excretion rate in relation to baseline (top), cross-sectional values of GFR (middle), and MABP (bottom) during treatment with.

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

The solid line represents the point estimate of the treatment ORs at various levels along the x-axis that ranges from the minimum to the maximum observed.

Algorithm for management of the patient with pain because of DSPN

Four–time point diurnal profiles of plasma glucose concentrations (A) and AUCs (B) over quintiles of HbA1c. ○, AUC1; •, AUC2; ▴, AUC2 − AUC1 (differences.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Cumulative mean numbers of confirmed (plasma glucose ≤3

Sensitivity and specificity of HbA1c, FPG, and 2hPG in identifying persons who developed diabetes within 10 years of screening among children and adolescents.

Presentation transcript:

Treatment response patterns and effect size over time in exclusively placebo-controlled trials. Treatment response patterns and effect size over time in exclusively placebo-controlled trials. A: Scatter plot of HbA1c reduction in 22 placebo group treatment arms and 47 antihyperglycemic medication treatment arms plotted with year of approval. A significant meta-regression predicting placebo response (dashed line) based on year of approval was found (P = 0.0013), with an R2 of 0.31. Placebo response increased by 0.035 for each year following 1999. The linear meta-regression to predict antihyperglycemic response (solid line) based on year of approval was also found to be significant (P = 0.0498), with an R2 of 0.076. Drug response increased by 0.017 for each year following 1999. B: Scatter plot of effect sizes for 47 treatment arms plotted with year of approval. A linear meta-regression predicting effect size based on year of approval was found not to be significant (P = 0.725), with an R2 of 0.003. Arif Khan et al. Dia Care 2018;41:994-1000 ©2018 by American Diabetes Association